COMPANY PROFILE

DISCO Pharmaceuticals

Biotechnological research as well as the development, production and distribution of biotechnological products and solutions of all kinds

Cologne, GermanyFounded 2022Biotech & Life Sciences

Valuation $100–250M Last recorded · 2025

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About DISCO Pharmaceuticals

DISCO Pharmaceuticals, a pioneering biotech startup based in Germany, is revolutionizing cancer treatment through its groundbreaking surfaceome discovery technology. The company focuses on identifying novel protein communities on the surface of cancer cells, specifically targeting Small Cell Lung Cancer (SCLC) and Colorectal Cancer. Unlike traditional methods such as proteomics, genome, or transcriptome sequencing, DISCO's technology provides a comprehensive map of the cancer cell surface, unveiling numerous new druggable targets. This innovative approach has the potential to significantly advance cancer therapies by offering more precise and effective treatment options.

Read full description

DISCO serves a diverse clientele that includes pharmaceutical companies, biotech firms, and research institutions. These clients are primarily involved in oncology research and drug development, seeking new targets for cancer treatment. The company operates in the highly competitive and rapidly evolving biopharmaceutical market, where innovation and technological advancements are key drivers of success.

The business model of DISCO Pharmaceuticals is centered around its proprietary surfaceome discovery technology. The company generates revenue through a combination of licensing agreements, collaborative research partnerships, and direct sales of its discovery services. By partnering with leading pharmaceutical companies and research institutions, DISCO not only accelerates the development of new cancer therapies but also ensures a steady stream of income.

DISCO recently secured EUR 20 million in seed financing, underscoring investor confidence in its transformative technology and business potential. The leadership team, led by CEO Roman Thomas, boasts extensive expertise in surface proteomics and oncology, with notable industry figures like Dieter Weinand, former CEO at Bayer Pharmaceuticals, and Carsten Reinhardt, CDO at Immatics, serving on the Board of Directors.

In summary, DISCO Pharmaceuticals is at the forefront of cancer treatment innovation, leveraging its unique surfaceome discovery technology to identify new therapeutic targets and drive advancements in oncology.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2022
Headquarters: Cologne, Germany
Employees: 37
Open positions: None listed
Dealroom signal: 87.7/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Spinout, Sustainable Development Goals, Biotech and Pharma, AI Drug Discovery, Techbio, Hard Tech, Techbio Drug Discovery
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SEEDOther financing	Dec 2025	$40M	$158M	Panakès Partners · M Ventures · Sofinnova Partners · AbbVie	↗
SEEDOther financing	Mar 2025	—	—	Sofinnova Partners · NRW.BANK · AbbVie · Panakès Partners	—

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

DISCO Pharmaceuticals website traffic

Latest recorded traffic for DISCO Pharmaceuticals is 1.2K monthly website visits, down 36.8% over the last three months. DISCO Pharmaceuticals's team grew 0% over the past year.

Latest monthly visits1.2K 3-month web change-36.8% 1-year team growth0%

Monthly website visitsJul 2023–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Research Associate/BTA/MTA – Target Validation and Drug Discovery (m/w/d)Cologne, Germany, Western Europe, Europe · Other · Aug 19, 2026

1 distinct opening shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
PEPepticomAn Artificial Intelligence (AI) company for the discovery of novel molecules in the Pharmaceutical and Agricultural markets	Jerusalem, Israel	Operational	16	$14M	$26M
OBOrionis BiosciencesPioneering technological innovation in genome-scale drug discovery and tunable molecular design of novel therapeutic drug modalities	Waltham, United States	Operational
EBEvaxion BiotechPioneering discovery of antigens and neo-epitopes for vaccines and antibodies using artificial intelligence	Hørsholm, Denmark	Operational
PHPhoreMostA new-model drug discovery company based in Cambridge, UK	Pampisford, United Kingdom	Operational
ATAchilles TherapeuticsAchilles Tx's mission is to develop next-generation, patient-specific therapies that harness the immune system to destroy cancer cells	Stevenage, United Kingdom	Closed
EXExogeneBiotechnology company accelerating target and TCR discovery for cancer cell therapies using AI-enabled TCR-antigen screening	Oxford, United Kingdom	Operational
MAMacomicsDeveloping precision medicines to modulate macrophages for the treatment of cancer	Edinburgh, United Kingdom	Operational
IBInterAx BiotechDelivering High-Quality Drug Candidates for GPCR Targets	Villigen, Switzerland	Operational